Issue 3/2023
Content (11 Articles)
Targeting IL-36 in Inflammatory Skin Diseases
Ryo Fukaura, Masashi Akiyama
Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus
Charl Verwey, Shabir A. Madhi
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Motahareh Arjomandnejad, Ishani Dasgupta, Terence R. Flotte, Allison M. Keeler
Advanced Delivery Strategies for Immunotherapy in Type I Diabetes Mellitus
Mingshu Huang, Weixing Chen, Min Wang, Yisheng Huang, Hongyu Liu, Yue Ming, Yuanxin Chen, Zhengming Tang, Bo Jia
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery
Amir Hossein Mohammadi, Zeinab Ghazvinian, Fatemeh Bagheri, Masako Harada, Kaveh Baghaei
Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome)
Valentina D. Gusarova, Maxim A. Smolov, Ivan V. Lyagoskin, Maksim B. Degterev, Elizaveta V. Rechetnik, Alexander V. Rodionov, Marina S. Pantyushenko, Rahim R. Shukurov
Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System
Hugo Jourdain, Léa Hoisnard, Emilie Sbidian, Mahmoud Zureik
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Kuan Peng, Joseph E. Blais, Nicole L. Pratt, Jeff Jianfei Guo, Jodie B. Hillen, Tyman Stanford, Michael Ward, Edward Chia-Cheng Lai, Ju-Young Shin, Xinning Tong, Min Fan, Franco W. T. Cheng, Jing Wu, Winnie W. Y. Yeung, Chak-Sing Lau, Wai Keung Leung, Ian C. K. Wong, Xue Li
Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing
Taihang Shao, Mingye Zhao, Leyi Liang, Wenxi Tang
Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial
Justin Stebbing, Yauheni Baranau, Valery Baryash, Vladimir Moiseyenko, Dmytro Boliukh, Nicoleta Antone, Alexey Manikhas, Anatolii Chornobai, Taehong Park, Eric Hyungseok Baek, Jaeyong Lee, Jiin Choi, Nahyun Kim, Keumyoung Ahn, Sang Joon Lee, Sunghyun Kim
Correction to: Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study
Douglas J. Rupert, Alyssa M. Jordan, Marina A. Ziemian, Rachel M. Brown, Neil S. Fleming, R. Craig Lefebvre